Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

SML3834

Sigma-Aldrich

Vorapaxar

≥98% (HPLC)

Synonym(s):

Ethyl [(3aR,4aR,8aR,9aS)-9(S)-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1(R)-methyl-3-oxonaphtho[2,3-c]furan-6(R)-yl]carbamate, MK 5348, MK-5348, MK5348, SCH 530348, SCH-530348, SCH530348

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C29H33FN2O4
CAS Number:
618385-01-6
Molecular Weight:
492.58
MDL number:
MFCD16038876
UNSPSC Code:
51111800
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Vorapaxar (MK-5348; SCH 530348) is an orally active, potent and selective thrombin receptor (PAR-1) antagonist with good selectivity over a panel of GPCRs, ion channels, and receptors, including PAR-2, PAR-3 and PAR-4. Vorapaxar inhibitis thrombin-induced calcium transient and thymidine incorporation in human coronary artery smoothmuscle cells (HCASMC; Ki = 1.1 and 13 nM, respectively), as well as aggregation in human platelet-rich plasma (PRP) induced by 10 nM thrombin or 15 μM haTRAP (IC50 = 47 and 25 nM, respectively), but not 20 μM ADP or 5 μM collagen. Oral administration (0.1 mg/kg to cynomolgus monkeys) prevents haTRAP-induced platelet aggregation ex vivo.

Pictograms

Environment
GHS09

Signal Word

Warning

Hazard Statements

H410

Precautionary Statements

P273 - P391 - P501

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study
European Journal of Pharmacology, 943, 175438-175438 (2023)
Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression
Hepatology (2023)
Samuel Chackalamannil et al.
Journal of medicinal chemistry, 51(11), 3061-3064 (2008-05-02)
The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service